MPO and ganglioneuroma: The continuous supply of vec-DNase I in active murine anti-MPO GN showed enhanced therapeutic efficacy over twice daily doses of ivDNase I, demonstrated by better preservation of glomerular histology and reductions in MPO-ANCA and albuminuria.